Inovio axes staffers, cancer program to 'sharpen focus,' save cash - FierceBiotech

Inovio axes staffers, cancer program to 'sharpen focus,' save cash  FierceBiotech

A few months after AstraZeneca's MedImmune unit walked away from some of its R&D work with the biotech, Inovio Pharmaceuticals is cutting 28% of its ...